Skip to main content
. 2008 Jul 30;3(7):e2844. doi: 10.1371/journal.pone.0002844

Figure 10. Bid is necessary for the synergistic activity between genotoxic drugs and TRAIL.

Figure 10

A, B) HeLa Control and HeLa Bid kd cells were treated with Etoposide (10 µM) or Oxaliplatin (30 µg/ml) for the indicated times; the pan-caspase inhibitor zVAD (100 µM) was added to the cells 1 h prior to treatment where specified; cell lysates were subjected to Western blotting with a polyclonal DR4, a polyclonal DR5, and a monoclonal β-actin antibody. C, D) HeLa control and HeLa Bid kd cells were pre-incubated with Etoposide (10 µM), Oxaliplatin (30 µg/ml), or vehicle for 16 h followed by treatment with TRAIL (10 ng/ml) for 3 h. Caspase-3 like activity was measured by cleavage of the fluorogenic substrate Ac-DEVD-AMC. Data are means+/−SD from n = 3 separate experiments. ∗ p<0.05: difference from Etoposide, Oxaliplatin or TRAIL individual treatments. # p<0.05 difference from control cells (Ctrl).